Intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG) ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 11 | 重症筋無力症 | 1 |
11. 重症筋無力症
臨床試験数 : 332 / 薬物数 : 234 - (DrugBank : 81) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04728425 (ClinicalTrials.gov) | August 28, 2020 | 14/7/2020 | Subcutaneous Immunoglobulin for Myasthenia Gravis | Efficacy and Safety of Subcutaneous Immunoglobulin in Patients With Myasthenia Gravis | Myasthenia Gravis | Drug: subcutaneous immunoglobulin (SCIG);Drug: intravenous immunoglobulin + subcutaneous immunoglobulin (SCIG) | University Health Network, Toronto | NULL | Recruiting | 18 Years | 100 Years | All | 30 | Phase 2 | Canada |